RAPT Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 0/6
RAPT Therapeutics's earnings are forecast to decline at 7.4% per annum while its annual revenue is expected to grow at 71% per year. EPS is expected to decline by 1.2% per annum. Return on equity is forecast to be -73% in 3 years.
Anahtar bilgiler
-7.4%
Kazanç büyüme oranı
-1.2%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | 71.0% |
| Gelecekteki özkaynak getirisi | -73.0% |
| Analist kapsamı | Good |
| Son güncelleme | 06 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -219 | -163 | -88 | 3 |
| 12/31/2025 | N/A | -114 | -119 | -108 | 8 |
| 12/31/2024 | N/A | -105 | -92 | -73 | 8 |
| 6/30/2024 | N/A | -120 | -105 | -105 | N/A |
| 3/31/2024 | N/A | -118 | -106 | -106 | N/A |
| 12/31/2023 | N/A | -117 | -98 | -97 | N/A |
| 9/30/2023 | N/A | -109 | -93 | -92 | N/A |
| 6/30/2023 | N/A | -99 | -89 | -87 | N/A |
| 3/31/2023 | 1 | -93 | -75 | -74 | N/A |
| 12/31/2022 | 2 | -84 | -72 | -71 | N/A |
| 9/30/2022 | 2 | -79 | -70 | -69 | N/A |
| 6/30/2022 | 3 | -76 | -65 | -64 | N/A |
| 3/31/2022 | 3 | -73 | -63 | -63 | N/A |
| 12/31/2021 | 4 | -69 | -62 | -61 | N/A |
| 9/30/2021 | 4 | -64 | -56 | -56 | N/A |
| 6/30/2021 | 5 | -60 | -54 | -53 | N/A |
| 3/31/2021 | 5 | -56 | -46 | -46 | N/A |
| 12/31/2020 | 5 | -53 | -41 | -40 | N/A |
| 9/30/2020 | 4 | -53 | -31 | -31 | N/A |
| 6/30/2020 | 2 | -49 | -33 | -33 | N/A |
| 3/31/2020 | 1 | -47 | -36 | -36 | N/A |
| 12/31/2019 | N/A | -43 | -36 | -35 | N/A |
| 9/30/2019 | N/A | -39 | -42 | -39 | N/A |
| 6/30/2019 | N/A | -40 | -39 | -36 | N/A |
| 3/31/2019 | N/A | -37 | -37 | -34 | N/A |
| 12/31/2018 | N/A | -36 | -36 | -33 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: RAPT is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: RAPT is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: RAPT is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: RAPT is forecast to have no revenue next year.
Yüksek Büyüme Geliri: RAPT is forecast to have no revenue next year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: RAPT is forecast to be unprofitable in 3 years.